UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2024
Commission File Number: 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot
Rehovot 7638517, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
CONTENTS
Evogene Ltd., or Evogene, today announces that its subsidiary, Biomica Ltd., or Biomica, presents positive
initial clinical data update from ongoing Phase 1 trial of microbiome-based therapeutic, BMC128, in patients with non-small cell lung cancer (NSCLC), melanoma, or renal cell carcinoma (RCC). A copy of the press release is attached as Exhibit 99.1
to this Report of Foreign Private Issuer on Form 6-K, or this Form 6-K.
The content of Exhibit 99.1 to this Form 6-K, excluding the statements of Prof. Gal Markel and of Biomica’s CEO,
is incorporated by reference in the registration statements on
Form F-3 (Securities and Exchange Commission (“
SEC”) File No.
333-277565), and Form S-8 (SEC File Nos.
333-193788,
333-201443,
333-203856 and
333-259215) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by
documents or reports subsequently filed or furnished.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: May 23, 2024
|
|
EVOGENE LTD.
(Registrant)
By: /s/ Yaron Eldad
Yaron Eldad
Chief Financial Officer
|